PROFILAKTIKA TOShNOTY I RVOTY PRI PROVEDENII TsITOSTATIChESKOY TERAPII U VZROSLYKh


Cite item

Full Text

Abstract

Тошнота и рвота при проведении цитостатической терапии воспринимаются пациентами как наиболее тягостное осложнение лечения. Основными препаратами для профилактики и терапии острой тошноты и рвоты являются антагонисты рецепторов серотонина третьего типа (5-HT3-рецепторов): гранисетрон, трописетрон, ондансетрон, доласетрон, палоносетрон. Дексаметазон назначают одновременно с антагонистами 5-HT3-рецепторов, т. к. он потенцирует их действие. Food and Drug Administration США одобрена новая трансдермальная форма гранисетрона (Sancuso), эффективная при проведении многодневной химиотерапии. Антиэметический препарат апрепитант (селективный блокатор NK1-рецепторов) рекомендован для профилактики тошноты и рвоты при высоко эметогенной химиотерапии и применении режима доксорубицин + циклофосфамид.

About the authors

I A Koroleva

M V Kopp

References

  1. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999;17:2971-94.
  2. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.
  3. Roila F, Basurto C, Bosnjak S, et al. Randomized, double-blind, dose-finding study of dexamethasone in prrowEventing acute emesis induced by anthracyclines, carboplatin or cyclophosphamide. J Clin Oncol 2004;22:725-9.
  4. Steven M, Grunberg, Paul J. et al. Control of Chemotherapy-Induced Emesis The New England journal of medicine 1993;329:1790-6
  5. Kaiser R, Sezer O, Papies A, et al. Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes J Clin Oncol 2002;20(12):2805-2811.
  6. Verna A, McDaniel RW, Nausea D. Vomiting, and retching: complex problems in palliative care. Cancer J Clin 2001;51:232-48.
  7. Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs 1996;52:639-48.
  8. Blower PR. A pharmacologic profile of oral granisetron. Eur J Cancer 1990;26(1):8-11.
  9. Lindley C, Blower P. Oral serotonin type 3 receptor antagonist for prevention of chemotherapy-induced emesis. Am J Health Sust Pharm 2000;15:1685-97.
  10. Van Wijngaarden I, Tulp MT, Soudijn W. The concept of selectivity in 5HT receptor research. Eur J Pharmacol 1990;138:301-12.
  11. Gebauer A, Merger M, Kilbinger H. Modulation by 5-HT3 receptor antagonist: correlation with anti-emetic response. Naunyn Schmiedebergs Arch Pharmacol 1993;347:137-40.
  12. Nelson Dr, Thomas DR. [3H]-BRL 43694 (granisetron), a specific ligand for 5-HT3 binding sites in rat brain cortical membranes. Biochem Pharmacol 1989;38:1693-95.
  13. Perez PR. Comparasion of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetigenic chemotherapy: doble-blinde, randomized, parallel study. J Clin Oncol 1989;16:754-60.
  14. Bishop JF, Matthews JP, Wolf MM, et al. A randomised trial of dexamethasone, lorazepam and prochlorperazine for emesis in patients receiving chemotherapy. Eur J Cancer 1992;28:47-50.
  15. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-8.
  16. Zaglama NE, Rosenblum SL, Sartiano GP, et al. Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy. Oncol 1986;43:27-32.
  17. Klygis LM. Dexamethasone-induced perineal irritation in head injury. Am J Emerg Med 1992;10:268.
  18. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. PrrowEvention of chemotherapy and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 1998;9:811-9.
  19. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. PrrowEvention of chemotherapy and radiotherapy-induced emesis: results of the 2004 Perugia Consensus Conference. Ann Oncol 2006;17:20-8.
  20. Cocquyt V, Van Belle S, Reinhardt RR, et al. L-758, 298, a prodrug for selective neurokinin-1 antagonist, L-754, 030, compared to ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001;37:835-42.
  21. Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapyinduced nausea and vomiting. Support Care Cancer 2001;9:350-54.
  22. Campos D, Periera JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by oral neurokinin-1 antagonist, MK-869, in combinatio with granisetron and dexametasone or with dexametasone alone. J Clin Oncol 2001;19(6):1759-67.
  23. Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prrowEvention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-300.
  24. Kirchner V, Aapro M, Terry J, et al. A double - blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nause and vomiting associated with chemotherapy. Eur J Cancer 1997;33(10):1605-10.
  25. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8.
  26. de Witt R, Herrstedt J, Rapoport B, et al. The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III trials. Eur J Cancer 2004;40:403-10.
  27. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK1 antagonist aprepitant for the prrowEvention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo-controlled trials. Eur J Cancer 2005;41:1278-85.
  28. Scmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexametasone, for antiemetic efficacy in hight-dose cisplatin trestment. Ann Oncol 2006 17(6);1000-6.
  29. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006;24:2932-47.
  30. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prrowEvention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30.
  31. Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prrowEvention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55.
  32. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000;342:1554-9.
  33. Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prrowEvention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosteron with ondansetron. Ann Oncol 2003;14:1570-7.
  34. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prrowEvention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3-receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-82.
  35. Passik SD, Loehrer PJ, Navari RJ, et al. A phase I trial of olanzapine (Zyprexa) for theprrow Evention of delayed emesis in cancer patients receiving chemotherapy: A Hoosier Oncology Group study. Proc ASCO 2002;21:374.
  36. Granisetron transdermal system: A new option to help prevent chemotherapy-induced nausea and vomiting. Clin J Oncol Nursing 2009;13(6):711-4.
  37. Morrow GR, Lindke J, Black PM, et al. Predicting development of anticipatory emesis in cancer patients: prospective examination of eight characteristics. J Pain Symptom Manage 1991;6:215-23.
  38. Montgomery GH, Bovbierg DH. Expectations of chemotherapy-related nausea: emotional and experiential predictors. Ann Behav Med 2003;25:48-54.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies